New shot aims to cut COPD attacks in half
NCT ID NCT07330310
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests an experimental injection called JKN2401 in 888 people with moderate-to-severe COPD. The goal is to see if it can safely reduce the number of serious flare-ups compared to a placebo. Participants will receive injections every four weeks and be monitored for about a year.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- JKN2401 injection
- What this could lead to
- If successful, JKN2401 could become a new treatment option to reduce the number of serious COPD flare-ups, helping patients breathe easier and stay out of the hospital.
- What could go wrong
- This is a large Phase 3 trial, but it's still experimental. The drug may not work better than placebo, and side effects are possible. Results will take time to analyze.
Why investors are watching
Joincare Pharmaceutical Group is running a Phase 3 trial of JKN2401, an injectable drug for moderate-to-severe COPD, with 888 participants. For a small company, this late-stage readout is a major event because a positive result could lead to regulatory approval and a new revenue source, while a negative result would likely set the program back significantly.
If it works: If the trial shows JKN2401 safely reduces COPD flare-ups or improves symptoms better than placebo, the company could seek approval to sell the drug. That approval would give Joincare a commercial product in a large patient population, which would be a meaningful milestone for a company of its size.
If it fails: Phase 3 trials often fail, and JKN2401 might not prove more effective than placebo or might show safety problems. A failure or delay would likely force the company to abandon or restart the program, wasting years of research and spending without a new product to show for it.
AI-written from the trial record. Speculative, and not investment advice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 888 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Mar 2026
An estimate. Start dates often move.
- Expected to finish
-
Nov 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Written informed consent; able and willing to comply with study procedures. * Adults with documented COPD diagnosis and medical history consistent with guideline criteria. * Relevant exposure history consistent with COPD (e.g., smoking and/or biomass exposure). * On stable, guideline-based maintenance COPD therapy prior to randomization, per investigator judgment. * Protocol-defined exacerbation history, symptom burden, and lung function at screening. Exclusion Criteria: * Current or past asthma, or other clinically significant respiratory disease that may confound assessment. * Clinically significant uncontrolled comorbidities that increase risk or interfere with participation/outcomes. * Immunodeficiency/immune dysregulation, active autoimmune disease requiring systemic immunosuppression, or significant opportunistic infection history. * Active clinically significant infection or recent infection requiring systemic therapy; recent protocol-defined COPD exacerbation. * Current/recent malignancy (except low-risk, adequately treated cancers per protocol) or clinically significant abnormal screening labs. * Prohibited recent vaccines or therapies, prior relevant biologic/targeted therapy exposure, severe hypersensitivity to biologics/IMP, pregnancy/breastfeeding, or inability to comply (including substance abuse), per investigator judgment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease (COPD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new inhaler match Symbicort's performance?
- Gentler exercise with a twist: could a tourniquet boost balance in lung disease?
- Personalized exercise plans could boost COPD recovery
- Can a nasal oxygen device prevent dangerous dips in blood oxygen during endoscopy for COPD patients?
- Drones may rush donor lungs to transplant patients, saving precious time
- Could a simple ultrasound predict ventilator success in elderly COPD patients?